QUIDEL CORPORATION (NASDAQ:QDEL) Files An 8-K Regulation FD DisclosureItem 7.01
QUIDEL CORPORATION (NASDAQ:QDEL) Files An 8-K Regulation FD Disclosure
Regulation FD Disclosure
In connection with Quidel Corporation’s previously announced participation at the Barclays Global Healthcare Conference on Wednesday, March 15, 2017, to be held at the Loews Miami Beach hotel in Miami Beach, Florida, the company will post a copy of its updated corporate presentation on the Investor Relations section of the Quidel website (http://ir.quidel.com) on Monday, March 13, 2017 at approximately 6:00 p.m. Eastern Time (3:00 p.m. Pacific Time).
About QUIDEL CORPORATION (NASDAQ:QDEL)
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. The Company’s diagnostic testing solutions primarily include applications in infectious diseases, women’s health and gastrointestinal diseases. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers. It markets its products in the United States through a network of national and regional distributors and a direct sales force. Internationally, it sells and markets primarily through distributor arrangements. Its diagnostic solutions are used in the detection and diagnosis of many critical diseases and other medical conditions, including autoimmune diseases, bone health and thyroid diseases. It provides diagnostic testing solutions under various brand names, including Quidel, QuickVue+ and Thyretain. QUIDEL CORPORATION (NASDAQ:QDEL) Recent Trading Information
QUIDEL CORPORATION (NASDAQ:QDEL) closed its last trading session up +0.05 at 21.03 with 208,618 shares trading hands.
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. The Company’s diagnostic testing solutions primarily include applications in infectious diseases, women’s health and gastrointestinal diseases. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers. It markets its products in the United States through a network of national and regional distributors and a direct sales force. Internationally, it sells and markets primarily through distributor arrangements. Its diagnostic solutions are used in the detection and diagnosis of many critical diseases and other medical conditions, including autoimmune diseases, bone health and thyroid diseases. It provides diagnostic testing solutions under various brand names, including Quidel, QuickVue+ and Thyretain. QUIDEL CORPORATION (NASDAQ:QDEL) Recent Trading Information
QUIDEL CORPORATION (NASDAQ:QDEL) closed its last trading session up +0.05 at 21.03 with 208,618 shares trading hands.
